X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 Nov 2024 05:07:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

13 Nov 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

08 Aug 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

27 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

29 May 2024 15:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 07:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

09 May 2024 05:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 May 2024 05:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 May 2024 15:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

30 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

29 Apr 2024 05:30:00 By Nasdaq GlobeNewswire